Objectives: To measure plasma concentrations of Tumor Necrosis Factor Receptor 2 in patients with acute leukemia, and to correlate the results with clinical features.
Material and Methods: Twenty-four patients with acute myeloid leukemia (AML), sixteen patients with acute lymphoblastic leukemia (ALL) and fifteen control subjects were included in the current study. Tumor Necrosis Factor Receptor 2 was measured in plasma of all subjects by enzyme-linked immunosorbent assay.
Results: Plasma Tumor Necrosis Factor Receptor 2 significantly increased in ALL compared to both control and AML cases.
Conclusions: TNFR2 may be used as a biomarker for differentiating between AML and ALL patients.
The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Download PDF 
Post
